Improving Buprenorphine Access While Reducing Diversion: Q&A with ASAM President

April 28th, 2016

Kelly J. Clark, MD, MBA, FASAM, DFAPA, President-elect, American Society of Addiction Medicine (ASAM), spoke recently at the National Rx Drug Abuse & Heroin Summit about ways to combat buprenorphine diversion while ensuring access to high quality treatment for opioid addiction. In this article, she responds to several questions posed by Join Together.

Read Q & A

Posted in Content


A Project of the Governor's Institute on Alcohol & Substance Abuse and the North Carolina Society of Addiction Medicine.
Funded wholly or in part by the federal Substance Abuse Prevention and Treatment Block Grant Fund (CFDA #93.959) as a project of the NC Division of Mental Health, Developmental Disabilities & Substance Abuse Services.